Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells

Takeshi Sawada,1,2,3 Masaru Watanabe,4,5 Yuu Fujimura,6 Shigehiro Yagishita,1 Tatsu Shimoyama,3 Yoshiharu Maeda,2 Shintaro Kanda,7 Mayu Yunokawa,8 Kenji Tamura,8 Tomohide Tamura,7 Hironobu Minami,2 Yasuhiro Koh6,4 and Fumiaki Koizumi1,9

1Shien-Lab, National Cancer Center Hospital, Tokyo; 2Medical Oncology/Hematology, Kobe University Graduate School of Medicine, Kobe; 3Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo; 4Drug Discovery and Development Division, Shizuoka Cancer Center Research Institute, Nagaizumi; 5Department of Internal Medicine, Wakayama Medical University, Wakayama; 6On-Chip Biotechnology, Tokyo; 7Department of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo; 8Department of Laboratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan

Key words
CTC, EGFR, PIK3CA, Scorpion ARMS, Flow cytometry, Cell sorter

Correspondence
Fumiaki Koizumi, Department of Laboratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan.
Tel: +81-(0)3-3823-2101; Fax: +81-(0)3-3823-5433; E-mail: fkoizumi@cick.jp

Funding Information
This work was supported in part by Advanced Research and Development Project on Diagnosis and Treatment for Early Stage of Cancer, Development of Automatic Testing System for Genetic Diagnosis using Peripheral Blood from New Energy and Industrial Technology Development Organization, and by a Grant-in-Aid for the Third-Term Comprehensive 10-Year Strategy for Cancer Control of Japan

Accepted December 17, 2015

Cancer Sci 107 (2016) 307–314
doi: 10.1111/cas.12868

Circulating tumor cells (CTC) originate from a primary solid tumor and are found transiting the circulatory system.

CTC are typically defined as nucleated cells lacking CD45 expression and expressing epithelial marker proteins, such as epithelial cell adhesion molecules (EpCAM) or cytokeratins. Enumeration and characterization of CTC are, as a “liquid biopsy,” expected to provide useful clinical information on prognosis, cancer staging, drug choice and therapeutic efficacy. Indeed, accumulating evidence suggests that CTC isolation from a blood sample may allow reliable early detection and molecular characterization of cancer at diagnosis, and may provide a minimally invasive method to guide and monitor the results of cancer therapy.

Methods for the enumeration and molecular characterization of circulating tumor cells (CTC) have been actively investigated. However, such methods are still technically challenging. We have developed a novel epithelial cell adhesion molecule independent CTC enumeration system integrated with a sorting system using a microfluidics chip. We compared the number of CTC detected using our system with those detected using the CellSearch system in 46 patients with various cancers. We also evaluated epidermal growth factor receptor (EGFR) and PIK3CA mutations of captured CTC in a study of 4 lung cancer and 4 breast cancer patients. The percentage of samples with detected CTC was significantly higher with our system (65.2%) than with CellSearch (28.3%). The number of detected CTC per patient using our system was statistically higher than that using CellSearch (median 5, 0; P = 0.000172, Wilcoxon test). In the mutation analysis study, the number of detected CTC per patient was low (median for lung, 4.5; median for breast, 5.5); however, it was easy to detect EGFR and PIK3CA mutations in the CTC of 2 lung and 1 breast cancer patient, respectively, using a commercially available kit. Our system is more sensitive than CellSearch in CTC enumeration of various cancers and is also capable of detecting EGFR and PIK3CA mutations in the CTC of lung and breast cancer patients, respectively.
system using FISHMAN-R with the CellSearch system for the enumeration of CTC. We also investigated the suitability of On-Chip Sort CTC capture for the analysis of EGFR mutations of advanced lung cancer patients and of PIK3CA mutations of advanced breast cancer patients in captured CTC using commercially available mutation detection kits, which have been approved in the USA, Japan and China, and are also in compliance with the European Directive 98/79/EC.

Material and Methods

**Buffer, reagents and antibodies.** BD Pharm Lyse lysing solution and Lyse/Fix Buffer were purchased from BD Biosciences (San Jose, CA, USA). The FcR blocking reagent and CD45 Microbeads (Dynabeads, DYNAL) were purchased from Miltenyi Biotec (Bergisch-Gladbach, Germany) and Invitrogen (Carlsbad, CA, USA), respectively. The FITC-conjugated anti-cytokeratin (CK) mAb CK3-6H5, phycoerythrin (PE)-conjugated anti-CD326 (EpCAM) mAb 9C4, and Alexa Fluor 700-conjugated anti-CD45 mAb F10-89-4 were purchased from Miltenyi Biotec, BioLegend (San Diego, CA, USA) and AbD Serotec (Oxford, UK), respectively.

**Cell culture.** Non-small cell lung cancer cell lines H1650, H1975, PC-9 and PC-14, and breast cancer cell line BT20 were used. PC-9 and PC-14 were kindly provided by Professor Hayata of Tokyo Medical College (Tokyo, Japan). H1650, H1975 and BT20 were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in RPMI-1640 (Sigma-Aldrich, St. Louis, MO) supplemented with 10% FBS (GIBCO, Life Technologies, Grand Island, NY, USA), penicillin, streptomycin and amphotericin B (10 000 U/mL, 10 mg/mL and 25 μg/mL, respectively [Sigma-Aldrich]) under a humidified atmosphere containing 5% CO₂ at 37°C.

**Circulating tumor cell enumeration and capture instrumentation.** The novel multicolor flow-cytometry-based CTC detection and capturing system of this article utilized FISHMAN-R (On-Chip Biotechnologies) and On-Chip Sort (On-Chip Biotechnologies), which is a cell-sorter integrated with FISHMAN-R. These devices use a disposable microfluidics chip and include a collection reservoir within which the sorted cells are stored (Fig. 1a–c). This design enables reduction of sample loss to the absolute minimum; specifically, the dead volume of analysis using this chip is <0.01 μL. This system therefore provides suitable conditions for the enumeration of rare cells such as CTC from patients’ blood. The details of the FISHMAN-R and On-Chip Sort were described previously.(8–10) Data analysis was performed using FlowJo software v7.6.5 (Tree Star, Ashland, OR, USA). The principle of sorting is described on the manufacturer’s website (http://www.on-chip.co.jp/en/index.html).

**Circulating tumor cell enrichment, immunofluorescent staining process and enumeration.** Circulating tumor cell enrichment from 4 mL of peripheral blood includes hemolysis and elimination of leukocytes by using CD45 antibody-conjugated microbeads. After the enrichment process, the CTC-enriched samples were subsequently fixed and stained using anti-CK-FITC, anti-EpCAM-PE and anti-CD45-Alexa Fluor 700 antibodies. Then, the samples were applied to FISHMAN-R or
On-chip Sort. A flowchart of this process including the CTC enrichment percentage is shown in Figure 2.

Our system defined CTC as CK+ and/or EpCAM+ and CD45− cells, with a diameter comparable to cell size. The parameter forward scatter/side scatter threshold was preset to allow detection of particles greater than approximately 6–8 μm in size so as to eliminate particles other than CTC, such as unbound microbeads and cell fragments.

Circulating tumor cells sorting and gene analysis of captured cells. Circulating tumor cell sorting was performed using On-chip Sort. DNA was isolated from sorted CTC by using the QIAamp DNA Micro Kit (QIAGEN, Hilden, Germany). Isolated DNA was analyzed using the Therascreen EGFR RQ PCR kit and the PI3K Mutation Test kit, which are based on ARMS and Scorpions PCR technologies (QIAGEN). The Therascreen EGFR RQ PCR kit amplifies and analyzes mutations in the EGFR gene including 19 deletions in exon 19 and amino acid changes of T790M in exon 20 or L858R in exon 21. The PI3K Mutation Test kit amplifies and analyzes the PIK3CA gene, including mutations in exons 9 and 20, which lead to E542K, E545K or H1047R amino acid changes.

Patient measurements and blood sample collection in the circulating tumor cell enumeration study. We analyzed 46 patients with various cancers and 5 healthy donors. To determine the threshold level of our method, we also analyzed 13 healthy donor samples. Healthy donors were defined as persons who had never been diagnosed with cancer before study enrollment. These healthy donor samples were collected and analyzed in three independent institutions. All patients and healthy donors in the present studies below provided informed consent and their participation in the studies was approved by the institutional review committee of the National Cancer Center. This work was carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Ten milliliters of peripheral blood was collected in a CellSave tube for CTC enumeration by CellSearch. A total of 5 mL of blood was collected in a standard 5-mL blood collection tube containing EDTA, and 4 mL of this blood was used for CTC enumeration by FISHMAN-R. The CellSave tube was delivered to an independent medical laboratory (GeneticLab, Sapporo, Japan), where CTC were enumerated using a CellSearch CTC Kit. To confirm the superiority of FISHMAN-R over CellSearch in detecting EpCAM-negative cells, 18 cells of the EpCAM-negative lung cancer cell line PC-14 were spiked into the blood of a healthy volunteer and the sample was analyzed in the same manner. In this study, all samples were analyzed by investigators who were blinded to the sample origin.

Method validation of circulating tumor cell sorting and mutation analysis in spiked blood samples. We previously reported that spiked-in rare tumor cells in blood can be sorted using On-chip Sort independent of EpCAM expression. To confirm the efficiency of On-chip Sort in capturing rare cells and to estimate the cell number threshold for mutation detection, we performed spike-in experiments using lung and breast cancer cell lines before the clinical trial.

Various numbers of PC-9 cells and BT-20 cells were picked up using a micropipette under an inverted microscope and were then added to a blood sample (4 mL). After these spiked samples were processed using our CTC enrichment method, the spiked cells were captured using On-chip Sort. The number of captured cells was visually counted under a fluorescence microscope, and we then calculated the sorting efficiency. To estimate the cell number threshold for detection of EGFR deletion mutations or the PIK3CA variant H1047R mutation in sorted cells, various numbers of PC-9 cells, H1650 cells and BT20 cells were spiked into 4 mL of blood, and the spiked cells were captured using On-chip Sort. Mutations in the captured cells were then analyzed using the gene analysis method described in the subsection above titled “Circulating tumor cells sorting and gene analysis of captured cells.”

Patient measurements and blood sample collection in the circulating tumor cell sorting and mutation analysis study. We analyzed 4 lung cancer and 4 breast cancer patients. The EGFR mutation status had been confirmed in surgical or biopsied specimens of the lung cancer patients before enrolment in this study. Breast cancer patients were enrolled without testing...
PIK3CA mutation status. Peripheral blood (4 mL) for this study was drawn from the study participants. CTC sorting using On-chip Sort and gene mutation analyses of captured cells were performed as described in the subsection above titled “Circulating tumor cells sorting and gene analysis of captured cells.”

**Table 1. Patient characteristics of, and number of circulating tumor cells detected in various cancer patients using FISHMAN-R and the CellSearch system**

| Pt | Primary   | Histology | Stage | Age/Sex | Metastatic site       | FISHMAN-R/4 mL | CellSearch/4 mL | CellSearch/7.5 mL |
|----|-----------|-----------|-------|---------|-----------------------|----------------|----------------|------------------|
| 1  | Lung      | SCLC      | IIIB  | 79/M    | —                     | 7              | 159.5          | 299              |
| 2  | Lung      | SCLC      | IIIB  | 59/F    | —                     | 18             | 3.7            | 7                |
| 3  | Lung      | SCLC      | IV    | 61/M    | Liver, bone           | 4              | 1.6            | 3                |
| 4  | Lung      | SCLC      | IV    | 66/M    | Liver                 | 7              | 5.3            | 10               |
| 5  | Lung      | NSCLC (Sq)| IIIB  | 66/M    | —                     | 0              | 0              | 0                |
| 6  | Lung      | NSCLC (Sq)| IV    | 59/F    | Retropitoneum         | 1              | 0.5            | 1                |
| 7  | Lung      | NSCLC (Sq)| IV    | 74/M    | Liver, bone           | 8              | 0              | 0                |
| 8  | Lung      | NSCLC (Sq)| IV    | 59/M    | Lung, LN              | 18             | 9.1            | 17               |
| 9  | Lung      | NSCLC (Ad)| IIIA  | 66/M    | —                     | 1              | 0              | 0                |
| 10 | Lung      | NSCLC (Ad)| IIIB  | 63/F    | —                     | 6              | 0              | 0                |
| 11 | Lung      | NSCLC (Ad)| IV    | 61/F    | Lung                  | 11             | 0              | 0                |
| 12 | Lung      | NSCLC (Ad)| IV    | 54/M    | Brain, Liver, kidney, bone, lung, pleura | 4              | 0              | 0                |
| 13 | Lung      | NSCLC (Ad)| IV    | 54/M    | Brain, adrenal, LN (abdominal) | 4              | 0.5            | 1                |
| 14 | Lung      | NSCLC (Ad)| IV    | 61/F    | Lung, liver           | 4              | 0              | 0                |
| 15 | Lung      | NSCLC (Ad)| IV    | 68/F    | Lung                  | 7              | 0.5            | 1                |
| 16 | Lung      | NSCLC (Ad)| IV    | 50/F    | LN                    | 8              | 0              | 0                |
| 17 | Lung      | NSCLC (Ad)| IV    | 51/M    | Pleura                | 11             | 0              | 0                |
| 18 | Lung      | NSCLC (Ad)| IV    | 73/F    | Bone                  | 14             | 43.2           | 81               |
| 19 | Lung      | NSCLC (Ad)| IV    | 61/F    | Brain                 | 15             | 0              | 0                |
| 20 | Lung      | NSCLC (Ad)| IV    | 75/M    | Lung                  | 16             | 0              | 0                |
| 21 | Lung      | NSCLC (other)| IV   | 63/M    | —                     | 3              | 0              | 0                |
| 22 | Lung      | NSCLC (LCNEC)| IV    | 71/M    | LN (neck)             | 3              | 0              | 0                |
| 23 | Breast    | IDC       | IIIC  | 72/F    | —                     | 5              | 0              | 0                |
| 24 | Breast    | ILC       | IV    | 53/F    | LN, liver, bone, stomach | 0              | 0              | 0                |
| 25 | Breast    | IDC       | IV    | 45/F    | Lung, liver, bone     | 1              | 0              | 0                |
| 26 | Breast    | Ad        | IV    | 74/F    | Bone                  | 2              | 0.5            | 1                |
| 27 | Breast    | IDC       | IV    | 58/F    | LN, lung, bone        | 3              | 0.5            | 1                |
| 28 | Breast    | IDC       | IV    | 58/F    | LN, lung, liver, bone, skin | 4              | 0.5            | 1                |
| 29 | Breast    | IDC       | IV    | 42/F    | Lung, bone, pleura    | 5              | 1.1            | 2                |
| 30 | Breast    | IDC       | IV    | 71/F    | Bone, pleura          | 10             | 0              | 0                |
| 31 | Breast    | IDC       | IV    | 56/F    | Liver, bone, stomach  | 20             | 6.9            | 12               |
| 32 | Breast    | IDC       | IV    | 35/F    | LN, lung, liver, bone | 23             | 23             | 23               |
| 33 | Breast    | IDC       | IV    | 45/F    | LN, bone              | 255            | 193.6          | 363              |
| 34 | Breast    | IDC       | IV    | 60/F    | Lung, liver, bone, brain | 443            | 874.7          | 1640             |
| 35 | Breast    | IDC       | IV    | 70/F    | Bone, pleura          | 829            | 402.7          | 755              |
| 36 | Cervix    | Sq        | IV    | 54/F    | Bone                  | 3              | 3              | 0                |
| 37 | Cervix    | Sq        | IV    | 60/F    | LN                    | 4              | 0              | 0                |
| 38 | Cervix    | Sq        | IV    | 47/F    | LN, lung              | 6              | 0              | 0                |
| 39 | Peritoneum| Ad        | IIIC  | 72/F    | Peritoneum            | 3              | 0              | 0                |
| 40 | Endometrium| Ad      | IV    | 66/F    | Peritoneum            | 2              | 0              | 0                |
| 41 | CUP       | Mesothelioma| IV    | 61/F    | Lung, peritoneum, pleura, subcutaneous | 0              | 0              | 0                |
| 42 | CUP       | Ad        | IV    | 46/M    | LN                    | 1              | 0              | 0                |
| 43 | CUP       | Ad        | IV    | 43/M    | LN, brain             | 2              | 0              | 0                |
| 44 | CUP       | Ad        | IV    | 68/M    | LN, lung              | 7              | 0              | 0                |
| 45 | CUP       | Ad        | IV    | 66/M    | LN, lung, brain, adrenal, thyroid | 9              | 0.5            | 1                |
| 46 | Head and Neck | SCC   | IV    | 61/M    | LN, liver, bone, bone marrow | 24             | 71.5           | 134              |

Ad, adenocarcinoma; CUP, cancer of unknown primary; F, female; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LCNEC, large cell neuroendocrine carcinoma; LN, lymph node; M, male; NSCLC, non-small cell lung cancer; Pt, patient number; SCLC, small cell lung cancer; Sq, squamous cell carcinoma; TKI, tyrosine kinase inhibitor; -, no metastases.
R Foundation for Statistical Computing, version 2.13.0), was used for statistical analyses.\(^{(1)}\)

**Results**

**Circulating tumor cell enumeration study.** We compared the sensitivity of our system with that of CellSearch for the detection of CTC in the blood of patients with various types of cancers. Eighteen patients with non-small cell lung cancer, 4 with small cell lung cancer, 13 with breast cancer, 5 with cancer of unknown primary, 3 with cervical cancer, 1 with peritoneum cancer, 1 with endometrial cancer and 1 with head and neck cancer were enrolled. Patient clinical data and the number of CTC detected in each patient examined using FISHMAN-R and CellSearch are shown in Table 1. The result of 13 healthy donor samples determined the threshold level of our system as 3 CTC/4 mL (Fig. 3f[i]). The number of CTC detected per patient using FISHMAN-R ranged from 0 to 829 (median, 5) and the CTC number of 65.2% (30/46) of the samples was above the threshold level. In contrast, using CellSearch, the CTC number of only 28.3% (13/46) of the samples was greater than the threshold level determined in a previous study (\(\geq 2/7.5\) mL).\(^{(1)}\) When the blood sample of a healthy donor that was spiked with 18 EpCAM-negative PC-14 cells was analyzed, while FISHMAN-R detected 10 of the spiked cells, CellSearch did not even detect a single spiked cell. In all of the other blood samples from the healthy donors, the number of CTC detected by FISHMAN-R and CellSearch was not greater than the threshold of each system (Fig. 3f[ii]). The results showed that our system was significantly more sensitive than that of the CellSearch system for the detection of CTC in breast cancer and non-small cell lung cancer patients \((P = 0.0342\) and 0.00558, Wilcoxon test; Fig. 3a,c). Although not reaching a level of statistical significance, the CTC detection sensitivity in the other cancer types, including small cell lung cancer and cancer with unknown primary, showed a trend toward being greater than that of the CellSearch system (Fig. 3b,d,e).

**Sorting efficiency and mutation analysis of sorted cells in spiked blood samples.** PC-9 cells (5, 20 or 100 cells) and BT-20 cells (10, 25, 50 or 100 cells) were spiked into 4 mL of peripheral blood, and the spiked cells were then recovered from the blood using On-chip Sort. Recovered cells were visually distinguished from leukocytes (Fig. 4a) and were then

![Fig. 3. Distribution of detected circulating tumor cell (CTC) from 4 mL of peripheral blood. The number of CTC detected in patients with (a) breast cancer, (b) small cell lung cancer, (c) non-small cell lung cancer, (d) cancer of unknown primary and (e) various cancers, and (f[ii]) in healthy donors using the On-chip system or the CellSearch system are plotted. Figure (f[i]) shows the results of 13 healthy donor samples obtained using the On-chip system in isolation from the study, which were collected and analyzed in three independent institutions. The CTC counts of the CellSearch system for 7.5 mL peripheral blood were normalized to 4 mL. The on-chip system defined a CTC as an EpCAM-positive and/or CK-positive and CD45-negative cell with a diameter comparable to the cell size. The CellSearch system defined a CTC as a cell that is both EpCAM-positive and CK-positive, CD45-negative and DAPI-positive. The statistical analysis used here was the Wilcoxon test.](www.wileyonlinelibrary.com/journal/cas)
counted under a fluorescent microscope. Regression analysis of the number of captured cells versus the number of spiked cells produced a correlation coefficient ($R^2$) of 0.9029 (Fig. 4b). The mean capture rates were $101.35 \pm 15.3\%$ for PC-9 and $77.0 \pm 8.1\%$ for BT-20 (Fig. 4c). To estimate the minimal number of CTC that are required for detection of mutations using our method, we performed further spike-in experiments. PC-9 cells (5, 10 or 100 cells) and H1650 cells (5, 10 or 30 cells), which have the EGFR exon 19 deletion mutation, and BT20 cells (10, 20 or 50 cells) that express the PIK3CA variant H1047R mutation were spiked into 4 mL of peripheral blood. Following processing of each sample in a manner simi-

Table 2. Evaluation of mutations in captured circulating tumor cells (CTC) of lung and breast cancer patients using On-Chip Sort

| Primary | Histology | Stage | Age/Sex | Metastatic site | Mutation Status | EGFR TKI | Detected CTC / 4 mL | Mutation detected in captured CTC |
|---------|-----------|-------|---------|----------------|----------------|----------|---------------------|----------------------------------|
| Lung    | NSCLC (Ad) | IV    | 74/F    | —              | Exon 19 deletion | Untreated | 3                   | None                             |
| Lung    | NSCLC (Ad) | IV    | 45/F    | LN, liver, bone, stomach | Exon 19 deletion | Treated   | 2                   | None                             |
| Lung    | NSCLC (Ad) | IV    | 75/F    | Lung, liver, bone | Exon 19 deletion | Treated   | 20                  | Exon 19 deletion                  |
| Lung    | NSCLC (Ad) | IV    | 76/F    | Bone          | Exon 19 deletion | Treated   | 6                   | Exon 19 deletion                  |
| Breast  | IDC       | IV    | 64/F    | LN, lung, bone | Unknown         | —         | 4                   | None                             |
| Breast  | IDC       | IV    | 77/F    | LN, lung, liver, bone, skin | Unknown | —         | 7                   | None                             |
| Breast  | IDC       | IV    | 75/F    | Lung, bone, pleura | Unknown     | —         | 3                   | None                             |
| Breast  | IDC       | IV    | 71/F    | Bone, pleura   | Unknown         | —         | 11                  | PIK3CA (H1047R) in exon 20       |

Ad, adenocarcinoma; F, female; IDC, invasive ductal carcinoma; LN, lymph node; NSCLC, non-small cell lung cancer.
Isolated circulating tumor cell (CTC) with a few leukocytes. (a) The photo shows a typical CK-/EpCAM-double positive cell (CTC) and CK-/EpCAM-double negative cells (leukocytes). The size of the CTC is 20 μm and that of leukocytes is approximately 6 μm. (b) An isolated EpCAM-negative and CK-positive CTC. The upper photo shows an EpCAM-negative and CK-positive CTC. The lower photo shows a typical EpCAM and CK-double positive CTC. Photos were taken using a BIOREVO BZ-9000.

Fig. 5. Isolated circulating tumor cell (CTC) with a few leukocytes. (a) The photo shows a typical CK-/EpCAM-double positive cell (CTC) and CK-/EpCAM-double negative cells (leukocytes). The size of the CTC is 20 μm and that of leukocytes is approximately 6 μm. (b) An isolated EpCAM-negative and CK-positive CTC. The upper photo shows an EpCAM-negative and CK-positive CTC. The lower photo shows a typical EpCAM and CK-double positive CTC. Photos were taken using a BIOREVO BZ-9000.

Discussion

We developed a novel multicolor flow cytometry-based CTC detection system, “FISHMAN-R,” and a CTC capture system, “On-chip Sort.” The detection rate of CTC in patients with various cancers using FISHMAN-R was 65.2% (n = 46), in contrast with 28.3% using CellSearch. In almost all of the samples, our system detected more CTC than CellSearch. However, there were some cases in which CellSearch detected many more CTC than our system. In those cases (Nos. 1, 33, 34, 35), the size of most of the CTC detected using CellSearch was 4–6 μm. Our system failed to enumerate these CTC because, based on previous studies, we assumed that the size of a CTC is larger than 6 μm. Therefore, in the present study, the lower limit of CTC detection size was set by reference to these previous data. Thus, the lower CTC counts obtained using our system compared with CellSearch possibly result from the difference in the size threshold. Other current CTC detection methodologies have reported that the size of CTC is larger than that detected using CellSearch in the present study. Optimization of the size threshold in our system in order to reduce CTC counting loss is a problem that remains to be solved.

Several studies have shown that the presence of EpCAM on tumor cells varies with tumor type. It has also been suggested that the low prevalence of CTC detected in patients with advanced non-small cell lung cancer using the CellSearch system may be due to the loss of EpCAM expression. Furthermore, a previous study suggested that EpCAM expression may limit CTC detection efficiency between technologies, especially in patients with metastatic lung cancer. Indeed, using our system we found that EpCAM-negative/CK-positive CTC, which could not be detected by CellSearch, can be detected in some cases, including in non-small cell lung cancer. Regarding the CTC detection rate in non-small cell lung cancer patients, our system showed a significantly higher rate than that of CellSearch (66.7 vs 11.1%). Such a discrepancy in the detection rate between our system and that of CellSearch indicates that our CTC detection system is superior to that of CellSearch due to its EpCAM independence. It has previously been reported that EpCAM-negative/CK-positive cells are often observed in disseminated tumor cells in bone marrow after chemotherapy. In addition, it has been reported that there is a type of CTC that co-expresses CK and mesenchymal components, the so-called EMT state, during the development of cancer. From the perspective of our results, cytokeratin (including epithelial marker-based detection) independent of EpCAM expression has the potential to detect more EMT cells or chemo-resistant cells than EpCAM-dependent detection. Additional staining of mesenchymal components in those cells may reveal the nature of those cells.

In the CTC sorting and mutation analysis study of lung and breast cancer patients, CTC were captured by On-chip Sort in 7 of 8 cases and it was possible to detect EGFR and PIK3CA mutations in the captured CTC. It is now clear that EGFR mutations have significant value for tailoring individualized EGFR tyrosine kinase inhibitor therapy in lung cancer. Moreover, the clinical importance of PIK3CA mutations is growing, with many phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR inhibitors currently being tested in preclinical and clinical settings. Therefore, easy analysis of such gene mutations with therapeutic targets is urgently needed. However, the availability of tumor specimens for testing of mutation status in the clinical setting is often limited. Moreover, there are currently considerable problems with invasive methods for obtaining tumor specimens and technical issues regarding tumor biopsy. A substitute approach for obtaining tumor specimens is the analysis of CTC, which enables tumor specimens to be easily obtained. CTC analysis can also be easily repeated, and might allow real-time monitoring of drug-sensitive and resistant mutations in individual patients. Because it remains unclear whether the CTC that are detected in blood are representative of all cancer cells in the body, further research will be required to determine the significance of the mutations detected in CTC. In the very limited number of patients that
were available to us, the results of mutation analysis of the CTC indicated that concordance between CTC and primary tissue in EGFR and PIK3CA mutation status was quite low. There has been a report of discrepancies in the EGFR mutation detection rate between primary tissue and CTC obtained by CellSearch when ultra-deep sequencing was used in mutational analysis.\(^\text{(27)}\) Similarly, discordance between primary tumor tissue and CTC in PIK3CA status has been reported.\(^\text{(28)}\) The low concordance rate between CTC and primary tissue in mutation detection that we obtained may be due to the low number of CTC, considering the results of our preclinical experiments; however, our result could also reflect CTC heterogeneity in mutations, as previously reported.\(^\text{(29)}\)

In 17 samples from healthy donors, our system detected 3 CTC in 2 samples and 1 CTC in 3 samples. There is still room for improvement in the specificity of CTC detection in our system. More samples of healthy donors should be evaluated to define a reliable threshold.

In summary, the results of clinical feasibility studies showed that our system is more sensitive than that of CellSearch for CTC enumeration in various cancers. In addition, our system is useful for the detection of EGFR and PIK3CA mutations in the captured CTC of lung and breast cancer patients, respectively, using commercially available kits. Our CTC capture and analysis approach may be used as a noninvasive repeatable biopsy method. It is desirable to further evaluate this system in the future using more clinical samples.

**Disclosure Statement**

Yuu Fujimura is a salaried employee of On-Chip Biotechnologies. The other authors have no conflict of interest to declare.

**References**

1. Allard WJ, Matera J, Miller MC et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. *Clin Cancer Res* 2004; 10: 6897–904.
2. Becker TM, Caixeiro NJ, Lin SH et al. New frontiers in circulating tumor cell analysis: a reference guide for biomolecular profiling toward translational clinical use. *Int J Cancer* 2014; 134: 2523–33.
3. Pantel K, Alix-Panabieres C. Real-time liquid biopsy in cancer patients: fact or fiction? *Cancer Res* 2013; 73: 6384–8.
4. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. *N Engl J Med* 2004; 351: 781–91.
5. Cohen SJ, Punt CJ, Iannotti N et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. *J Clin Oncol* 2008; 26: 3213–21.
6. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. *Clin Cancer Res* 2008; 14: 6302–9.
7. Hou JM, Krebs MG, Lancashire L et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. *J Clin Oncol* 2012; 30: 525–32.
8. Watanabe M, Uehara Y, Yamashita N et al. Multicolor detection of rare tumor cells in blood using a novel flow cytometry-based system. *Cytometry A* 2013; 85: 206–13.
9. Watanabe M, Serizawa M, Sawada T et al. A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in blood. *J Transl Med* 2014; 12: 143–54.
10. Takao M, Takeda K. Enumeration, characterization, and collection of intact circulating tumor cells by cross-contamination-free flow cytometry. *Cytometry A* 2011; 79: 107–17.
11. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. *Bone Marrow Transplant* 2013; 48: 452–8.
12. Desitter I, Guerreouahen BS, Benali-Furet N et al. A new device for rapid isolation by size and characterization of rare circulating tumor cells. *Anti-cancer Res* 2011; 31: 427–41.
13. Vona G, Sabile A, Louha M et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. *Am J Pathol* 2000; 156: 57–63.
14. Stott SL, Hsu CH, Tsukrov DI et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. *Proc Natl Acad Sci USA* 2010; 107: 18392–7.